DBV Technologies (DBVT) Lowered to Hold at BidaskClub
BidaskClub lowered shares of DBV Technologies (NASDAQ:DBVT) from a buy rating to a hold rating in a research report report published on Thursday morning.
DBVT has been the subject of a number of other reports. Societe Generale downgraded DBV Technologies from a buy rating to a sell rating in a research note on Tuesday, October 24th. Zacks Investment Research raised DBV Technologies from a hold rating to a buy rating and set a $32.00 target price for the company in a research note on Tuesday, October 24th. JMP Securities began coverage on DBV Technologies in a research note on Friday, November 17th. They set an outperform rating for the company. Barclays cut their target price on DBV Technologies from $58.00 to $30.00 and set an overweight rating for the company in a research note on Monday, October 23rd. Finally, ValuEngine downgraded DBV Technologies from a hold rating to a sell rating in a research note on Tuesday, September 26th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and eight have assigned a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $49.63.
DBV Technologies (NASDAQ:DBVT) opened at $25.05 on Thursday. DBV Technologies has a one year low of $20.58 and a one year high of $50.57.
COPYRIGHT VIOLATION NOTICE: “DBV Technologies (DBVT) Lowered to Hold at BidaskClub” was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/dbv-technologies-dbvt-lowered-to-hold-at-bidaskclub/1817358.html.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.